Immunotherapy: New Cancer Detection Approach
- Cancer cells ofen evade the immune system by blending in, effectively becoming invisible.
- Laure Vincent-Fabre, focuses on equipping T cells - key players in the immune response - with synthetic receptors.
- Instead of directly targeting MUC1, the researchers took a unique approach.
New Immunotherapy Strategy Boosts Cancer Cell Detection
Table of Contents
Published September 30, 2025
Cancer cells ofen evade the immune system by blending in, effectively becoming invisible. This is largely due to a lack of specific markers, or signals, that would alert immune cells to their presence. A team of researchers at the Institut Curie and Inserm (the French National Institute of Health and Medical Research) have been working to overcome this challenge, developing a novel immunotherapy approach to help the immune system more effectively identify and attack cancerous cells.
Engineering Immune Cells to Recognize Cancer
the innovative strategy, detailed in research led by Dr. Sébastien Lugtenberg and Dr. Laure Vincent-Fabre, focuses on equipping T cells – key players in the immune response – with synthetic receptors. Thes receptors are designed to recognize a common molecule found on the surface of many cancer cells, but not typically present on healthy cells. Specifically, the team targeted the MUC1 protein, which is often overexpressed in various cancers, including breast, lung, and ovarian cancers.
Instead of directly targeting MUC1, the researchers took a unique approach. They engineered the T cells to recognize fragments of antibodies that *bind* to MUC1. This indirect recognition method proved more effective at activating the T cells and triggering an immune response. This is because the engineered receptors, called chimeric antigen receptors (cars), are more readily activated when they recognize the antibody fragments.
Promising Results in Preclinical Trials
Initial testing,conducted in vitro and in mouse models,demonstrated a important increase in the ability of the engineered T cells to specifically target and destroy cancer cells. The study, published on September 29, 2024, showed that these CAR T-cells were able to effectively eliminate cancer cells expressing MUC1, while leaving healthy cells unharmed. The researchers observed a robust anti-tumor response in the animal models.
Crucially, the team also addressed a common issue with CAR T-cell therapy: potential toxicity. By using the indirect recognition method, they minimized the risk of the T cells attacking healthy tissues that might also express low levels of MUC1.This targeted approach is a significant step towards safer and more effective cancer immunotherapy.
Looking Ahead: Clinical trials and Future Applications
The researchers are now preparing to launch clinical trials to evaluate the safety and efficacy of this new immunotherapy approach in human patients. these trials, expected to begin in 2025, will initially focus on patients with advanced solid tumors that express MUC1.
Beyond MUC1, the team believes this strategy coudl be adapted to target othre cancer-associated molecules. The versatility of the approach allows for the advancement of CAR T-cells that can recognize a wide range of cancer types, potentially revolutionizing cancer treatment. The Institut Curie website provides further facts on their research programs.